FinnGen, a large-scale academic – industry, genome research collaboration in Finland now includes eleven industry partners with the addition of the Janssen Pharmaceutical Companies of Johnson & Johnson and Maze Therapeutics.

We are excited to announce that the FinnGen data freeze 2 results and summary statistics are now publicly available!

What are the benefits of FinnGen and Finland for our industry partners? This autumn we took the opportunity to interview some representatives of our pharmaceutical partners who wanted to share their experiences of FinnGen.

Results based on the FinnGen data are presented in several talks and posters during the 69th Annual Meeting of the American Society of Human Genetics (ASHG) in Houston, October 15-19. Come and meet our researchers!

The next FinnGen Face-to-Face meeting will be organized 11 - 12 September in Helsinki. 

With this new animation we hope to be able to explain all the essential characteristics of the FinnGen study in a way that is both entertaining and enlightening.

HELSINKI, Finland, January 22, 2019

GSK and Sanofi have joined the FinnGen study, a large public private partnership aiming to collect and analyse genome and health data from 500 000 Finns and thereby generate novel medically and therapeutically relevant insights.

Several FinnGen researchers are participating in the ASHG 2018 meeting.

The next FinnGen Face-to-Face meeting will be organized 24 - 25 October 2018 in Helsinki. 

A unique study that combines genome information with digital health care data has been launched in Finland. The FinnGen study plans to analyse up to 500 000 unique blood samples collected by a nation-wide network of Finnish biobanks. The goal is to deepen our understanding about the origins of diseases and their treatment. The project is expected to continue for six years, with a current budget of €59M.